Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Codexis, Inc.NASDAQ: CDXS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $8.7M (cash outflow) fell 57.9% year over year, behind the -57.0% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Net income amounted to 62.5% of revenue in FY2025, down 47.5 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$32.78M (-25.5%) for the fiscal year ending Dec 2026, a step up from the -32.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.7M-190.7% QoQ
Last fiscal yearDec 2025
-$43.97M-32.6% YoY
LTMMar 2026
-$31.99M-57.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-57.9%+7.2%+65.2 pp
1 year-32.6%-25.5%+7.2 pp
3-year CAGR+9.4%-41.8%-51.2 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(43.97M) USD
Year-over-year change
+32.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CDXS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -57.0% is the lowest of 10, against a peer median of -0.6%.
  • Net income amounts to 41.0% of revenue for CDXS, versus a peer median of 678.5%.
CDXS Competitors
Net Income for CDXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$282.61M USD+66241.3%+67.6%9554.2%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$123.33M USD+55.2%-13.9%356.9%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$103.8M USD+0.5%-6.4%297.8%
IVVDInvivyd, Inc.LTM Mar 2026$77.6M USD-45.6%-39.9%138.9%
TARAProtara Therapeutics, Inc.LTM Mar 2026$63.31M USD+39.4%-4.5%—
OABIOmniAb, Inc.LTM Mar 2026$54.29M USD-11.4%+42.6%187.8%
IPHAInnate Pharma S.A.FY2025€49.18M EUR-0.6%-5.4%1764.5%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$47.84M USD-17.8%-11.7%2454.6%
CDXSCodexis, Inc.LTM Mar 2026$31.99M USD-57.0%+9.4%41.0%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$31.7M USD-25.4%-22.3%1000.2%
Peer median (excluding CDXS) —-0.6%-6.4%678.5%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.28M)(33.59M)(76.24M)(65.28M)(43.97M)
Depreciation & Amortization5.95M10.25M9.92M4.95M5.25M
Deferred Income Tax(2.89M)0000
Stock-Based Compensation11.59M14.53M9.97M13.09M9.62M
Change in Working Capital(7.62M)21.57M(18.22M)(12.02M)6.42M
Accounts Receivables(15.57M)(3.23M)20.25M1.25M8.51M
Inventory(196K)(869K)(656K)886K(19K)
Accounts Payables268K207K2.29M(2.57M)(1.29M)
Other Working Capital7.88M25.46M(40.1M)(11.59M)(784K)
Other Non-Cash Items(19K)(1.48M)21.93M9.85M3.31M
Operating Cash Flow(14.27M)11.28M(52.64M)(49.41M)(19.38M)
Capital Expenditures(13.83M)(8.31M)(4.42M)(4.31M)(4.47M)
Acquisitions (Net)36K29K751K87K5K
Purchases of Investments(7.63M)(5.3M)(1.19M)(90.24M)(57.16M)
Sales of Investments(36K)(29K)440K37.47M85.13M
Other Investing Activities36K29K(440K)00
Investing Cash Flow(21.42M)(13.58M)(4.86M)(56.98M)23.5M
Debt Repayment00029.52M9.89M
Common Stock Issued4.97M913K8.65M31.32M18.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.21M)(1.49M)(485K)(318K)0
Financing Cash Flow3.77M(575K)8.17M60.52M27.93M
Effect of Forex Changes00000
Net Change in Cash(31.92M)(2.87M)(49.33M)(45.87M)32.05M
Free Cash Flow(28.1M)2.98M(57.06M)(53.72M)(23.85M)

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.